Synklino Nets €29.8M Series A Funding for Cytomegalovirus Drug Trial
June 8, 2022
Synklino, a Danish biotech, announced on Monday, June 6th, that it received €29.8 in a Series A funding round for a Phase 1 clinical trial for its cytomegalovirus (CMV) therapeutic. CMV is a common infectious agent that leads to serious complications following organ transplantation. The company hopes to use this funding to start trials and set up process to expedite the drug’s development
According to Thomas Kledal, co-founder and CEO of Synklino, “This financing round is a game changer for Synklino. We are now able to prepare and initiate clinical trials with SYN002 in organs and in patients concurrently, providing more paths to reach significant and value creating milestones in a shorter timeline. Since the capital raise in November 2021, we have had strong progress in our preclinical activities and are on track to deliver on our goal for the first half of 2023 of completing our clinical trial application.”
Click here to read more.
(Source: Labiotech.eu, June 6th, 2022)